Search research articles
Contact Us
Filters
Showing results (81-90 of 115) with videos related to
Page
of 12
Sort By:
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
June 25, 2026
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years
A Pretta, G Rebecchi, G Maddalena, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
M Tempero, D-Y Oh, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study
S J Klempner, R A Pazo-Cid, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
E Dell'Aquila, C Cremolini, T Zeppola, et al.
ESMO Open
|
June 13, 2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A Boccaccino, B Borelli, R Intini, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
May 7, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J Taieb, J Seligmann, D Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2018
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
T Yoshino, D C Portnoy, R Obermannová, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 115) with videos related to
Sort By:
Page
of 12
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
June 25, 2026
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years
A Pretta, G Rebecchi, G Maddalena, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
M Tempero, D-Y Oh, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study
S J Klempner, R A Pazo-Cid, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
E Dell'Aquila, C Cremolini, T Zeppola, et al.
ESMO Open
|
June 13, 2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A Boccaccino, B Borelli, R Intini, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
May 7, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J Taieb, J Seligmann, D Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2018
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
T Yoshino, D C Portnoy, R Obermannová, et al.
Page
of 12